Related Experiment Video
Updated: Apr 28, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Differentiating HIV-associated nephropathy from antiretroviral drug-induced nephropathy: a clinical challenge
Neelja Kumar1, Mark A Perazella
1Section of Nephrology, Department of Medicine, Yale University School of Medicine, BB 114, 330 Cedar Street, New Haven, CT, 06520-8029, USA.
Insights
Combination antiretroviral therapy (cART) benefits HIV patients but can cause kidney disease. Differentiating HIV-associated nephropathy (HIVAN) from cART nephrotoxicity is crucial for effective patient management.
Area of Science:
- Nephrology
- Infectious Diseases
- Pharmacology
Background:
- Combination antiretroviral therapy (cART) has improved outcomes for HIV-infected patients.
- Kidney disease remains a significant complication in this population.
- The landscape of renal complications has shifted from HIV-associated nephropathy (HIVAN) to include drug toxicities and comorbidities.
Purpose of the Study:
- To review HIV-associated nephropathy (HIVAN) and cART-related kidney disease.
- To discuss clinical and laboratory data for differentiating these conditions.
- To highlight the role of kidney biopsy in diagnosis.
Main Methods:
- Literature review of HIVAN and cART nephrotoxicity.
- Analysis of clinical and laboratory differentiating features.
- Discussion of diagnostic challenges and the utility of kidney biopsy.
Main Results:
- Distinguishing HIVAN from cART nephrotoxicity can be challenging.
- Clinical and laboratory data offer clues but are often insufficient.
- Kidney biopsy is frequently necessary for definitive diagnosis.
Conclusions:
- HIVAN and cART nephrotoxicity are important causes of kidney disease in treated HIV patients.
- Accurate differentiation is essential for appropriate management.
- Kidney biopsy remains a critical diagnostic tool.
Abstract:
With the introduction of potent combination antiretroviral therapy (cART) into clinical practice, HIV-infected patients have garnered much benefit. However, kidney disease continues to be a potential complication in this group. Whereas HIV-associated nephropathy (HIVAN) was the major renal complication prior to cART, co-morbid diseases and adverse renal effects of various drugs, in particular cART, now complicate the landscape. Clinicians now must differentiate HIVAN from cART nephrotoxicity. While sometimes this is easy and relatively straightforward, often the clinician faces a difficult challenge distinguishing these two etiologies of kidney disease. This review will discuss HIVAN and cART-related kidney disease and review the clinical and laboratory data that may be useful in differentiating these processes. Often, however, kidney biopsy may be required to differentiate HIVAN from cART nephrotoxicity as well as other kidney lesions associated with concurrent co-morbidities, both infectious and non-infectious.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Diabetic Nephropathy
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Pharmacokinetics in Pediatric Patients: Drug Excretion
Nephrotic Syndrome I : Introduction
Acute Kidney Injury II: Pathophysiology

